Hospital
Southwest Volusia Healthcare Corporation
Southwest Volusia Healthcare Corporation was paid $17.10M by Medicaid between Jan 2018 and Dec 2024, across 192 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoSOUTHWEST VOLUSIA HEALTHCARE CORPORATION
ORANGE CITY, FL 32763
ORANGE CITY, FL 32763
33aNPI1700978558assigned 09/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.10M
24GClaims505,729
24DCodes billed192
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#25 of 163
Median peer was paid$4.77M
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,959 | $414K | |
| 2019 | 79,850 | $2.09M | |
| 2020 | 77,100 | $2.03M | |
| 2021 | 95,510 | $3.03M | |
| 2022 | 116,625 | $3.95M | |
| 2023 | 72,050 | $3.52M | |
| 2024incomplete | 36,635 | $2.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 48,197 | 44,921 | $4.99M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 29,625 | 26,590 | $2.80M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 13,307 | 11,709 | $968K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.6% | 9,905 | 8,715 | $962K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 4,074 | 3,704 | $734K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.5% | 6,141 | 5,520 | $603K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 6,371 | 6,022 | $543K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 5,357 | 4,594 | $534K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.5% | 2,816 | 2,580 | $421K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 4,698 | 2,683 | $415K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,816 | 1,621 | $249K |
| 0225U | 1.4% | 4,283 | 4,158 | $238K |
180 more codes
| 80053 | Comprehensive metabolic panel | 1.3% | 30,687 | $230K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 5,869 | $227K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 2,420 | $186K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 4,279 | $172K |
| 59025 | Fetal non-stress test | <1% | 1,753 | $168K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,696 | $167K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 12,793 | $154K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,794 | $151K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 949 | $149K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,166 | $141K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,295 | $117K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,628 | $101K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,804 | $86K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 994 | $85K |
| 82947 | <1% | 6,445 | $81K | |
| 87807 | <1% | 1,087 | $79K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,262 | $77K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,858 | $74K |
| 81003 | <1% | 9,829 | $58K | |
| 81001 | <1% | 10,524 | $58K | |
| 73630 | <1% | 1,381 | $58K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 764 | $58K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 856 | $45K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,640 | $44K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,359 | $44K |
| 73130 | <1% | 1,048 | $38K | |
| 81025 | <1% | 6,762 | $36K | |
| 73610 | <1% | 980 | $33K | |
| G0378 | Hospital observation service, per hour | <1% | 2,494 | $33K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 551 | $32K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,213 | $30K |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 472 | $26K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 112 | $23K |
| 73110 | <1% | 610 | $22K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,026 | $22K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 655 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,803 | $20K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 608 | $20K |
| 73562 | <1% | 921 | $20K | |
| 72100 | <1% | 957 | $19K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,134 | $18K |
| 87070 | <1% | 4,046 | $17K | |
| 73030 | <1% | 824 | $17K | |
| 93971 | <1% | 494 | $16K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 680 | $15K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 58 | $14K |
| 84703 | <1% | 4,880 | $13K | |
| 76377 | <1% | 1,049 | $11K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 569 | $11K |
| 74018 | <1% | 631 | $11K | |
| 96376 | <1% | 1,412 | $11K | |
| 84484 | <1% | 9,862 | $11K | |
| 92650 | <1% | 353 | $11K | |
| 84702 | <1% | 1,987 | $10K | |
| 86900 | <1% | 1,682 | $10K | |
| 76801 | <1% | 1,088 | $9K | |
| 80050 | General health panel | <1% | 458 | $9K |
| 92587 | <1% | 218 | $9K | |
| 73502 | <1% | 244 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,944 | $9K |
| 86850 | <1% | 676 | $9K | |
| 72040 | <1% | 282 | $9K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 172 | $8K |
| 85610 | <1% | 5,574 | $7K | |
| 87040 | <1% | 4,888 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 70 | $7K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 82 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,439 | $6K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 76 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 75 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 619 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,499 | $5K |
| 83880 | <1% | 2,922 | $5K | |
| 80061 | Lipid panel | <1% | 2,426 | $5K |
| 85730 | <1% | 4,865 | $4K | |
| 86901 | <1% | 1,671 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 51 | $4K |
| 83735 | <1% | 5,757 | $4K | |
| 83605 | <1% | 3,366 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,357 | $4K |
| 73080 | <1% | 169 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 668 | $4K |
| 77066 | Tomosynthesis, mammo | <1% | 67 | $3K |
| 85027 | <1% | 2,208 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,641 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 51 | $3K |
| 01999 | <1% | 814 | $3K | |
| 80306 | <1% | 144 | $3K | |
| 82565 | <1% | 1,541 | $3K | |
| 87186 | <1% | 1,741 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,487 | $2K |
| 83690 | <1% | 9,704 | $2K | |
| 93970 | <1% | 16 | $2K | |
| 74022 | <1% | 54 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,089 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,850 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 483 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,241 | $2K |
| 87077 | <1% | 1,418 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 319 | $2K |
| 80305 | <1% | 394 | $2K | |
| 73590 | <1% | 33 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 706 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 120 | $1K |
| 85014 | <1% | 70 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 14 | $1K |
| 84520 | <1% | 60 | $1K | |
| 80047 | <1% | 15 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 623 | $877.56 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,657 | $863.49 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,130 | $855.26 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 795 | $811.91 |
| 87205 | <1% | 592 | $734.61 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 618 | $701.79 |
| 73140 | <1% | 26 | $695.25 | |
| 76536 | <1% | 14 | $674.13 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 101 | $673.20 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 421 | $656.99 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 155 | $629.58 |
| 86140 | <1% | 1,236 | $626.10 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 35 | $573.20 |
| 87081 | <1% | 2,733 | $514.15 | |
| 84439 | <1% | 1,011 | $449.63 | |
| 82043 | <1% | 355 | $429.15 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,789 | $403.56 |
| 82570 | <1% | 732 | $390.57 | |
| 85652 | <1% | 662 | $347.86 | |
| 87210 | <1% | 1,360 | $338.17 | |
| 76775 | <1% | 14 | $328.83 | |
| 85379 | <1% | 1,066 | $316.44 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 24 | $299.32 |
| 12001 | <1% | 41 | $286.89 | |
| 94760 | <1% | 474 | $251.21 | |
| 72131 | <1% | 31 | $215.42 | |
| 82550 | <1% | 582 | $209.87 | |
| 87270 | <1% | 710 | $204.84 | |
| 99152 | <1% | 12 | $199.89 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 915 | $174.87 |
| 90715 | <1% | 414 | $167.56 | |
| 74021 | <1% | 16 | $152.60 | |
| 82607 | <1% | 227 | $143.88 | |
| 83540 | <1% | 107 | $138.41 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 66 | $136.12 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 570 | $132.23 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,092 | $128.08 |
| 73564 | <1% | 13 | $116.67 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 120 | $114.59 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 62 | $94.90 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 522 | $86.26 |
| 73090 | <1% | 50 | $65.58 | |
| 94761 | <1% | 112 | $59.36 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 31 | $51.46 |
| 82247 | <1% | 25 | $47.22 | |
| 85007 | <1% | 678 | $40.53 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 141 | $39.06 |
| 84100 | <1% | 134 | $4.81 | |
| 82077 | <1% | 452 | $3.34 | |
| 84132 | <1% | 47 | $2.95 | |
| 84156 | <1% | 44 | $2.94 | |
| 84550 | <1% | 25 | $1.47 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $0.99 |
| 87420 | 0% | 378 | $0.00 | |
| 80179 | 0% | 123 | $0.00 | |
| 84145 | 0% | 166 | $0.00 | |
| 80143 | 0% | 77 | $0.00 | |
| 29125 | 0% | 39 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 308 | $0.00 |
| 12011 | 0% | 31 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 52 | $0.00 |
| 84466 | 0% | 58 | $0.00 | |
| 82728 | 0% | 97 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 142 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 420 | $0.00 |
| 83615 | 0% | 57 | $0.00 | |
| 82803 | 0% | 58 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 108 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 18 | $0.00 |
| 94762 | 0% | 60 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 100 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZILL, KENNETH (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Southeast Volusia Healthcare Corporation | New Smyrna Beach, FL | $4.11M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.